Amicus Therapeutics announces 3-in-3 strategy for the next generation ERTs Amicus Therapeutics provided its FY14 strategic outlook and financial guidance. Key Highlights include: Amicus announces "3-in-3" strategy for three next-generation Enzyme Replacement Therapies, or ERTs, expected to enter the clinic in next three years with lead programs in Fabry, Pompe and Mucopolysaccharidosis I; preclinical proof-of-concept data for next-generation ERTs for Fabry and Pompe to be featured at Lysosomal Disease Network WORLD Symposium and American College of Medical Genetics meetings in 1H14; data from global registration studies of migalastat HCl monotherapy for Fabry disease expected to include complete 12- and 24-month data from Study 011 in 2Q14 and 18-month clinical data from Study 012 in 2H14. Company also stated "As we enter 2014, Amicus is strongly positioned to continue our focus on advancing a pipeline of next-generation enzyme replacement therapies for patients with lysosomal storage diseases. "
News For FOLD From The Last 14 Days
Check below for free stories on FOLD the last two weeks.